Traded Jun 1, 2026 · Filed Jun 2, 2026
The boss of Gilead Sciences sold $1.43M of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,428,983
Shares × reported transaction price
25 days after results of May 7, 2026, 64 days before results of Aug 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $131.10 on Jun 1, 2026, 24% above its 52-week low and 16% below its high, after a 5% drop over the previous 30 trading days
52-week range $105.93 (Jun 25, 2025) to $155.80 (Feb 11, 2026), 50% of the way up, from 251 adjusted closes. 30 trading days earlier: $137.64 on Apr 17, 2026. Describes the past only, not a forecast
A WARN layoff notice covering 108 workers was filed in California on April 30, 2026.
From the official state WARN list, 32 days before the trade. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Hepcludex on May 22, 2026, 10 days before this trade.
Biologic approved. Active ingredient: Bulevirtide-Gmod. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -5.8% | -3.8% | -2.0% |
| 30 days | +0.5% | -0.4% | +0.9% |
| 90 days | +16.2% | +1.0% | +15.2% |
Past results only. Not a forecast.
CEO sold ~$1.5M of Gilead Sciences
Scheduled in advanceCEO sold ~$394K of Gilead Sciences
Scheduled in advance2 different filers disclosed GILD within 90 days. Disclosed 44 days after the transaction; reported as an official range, not an exact amount.
Congress trade